Natixis Acquires 65 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Natixis boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,986 shares of the medical research company’s stock after buying an additional 65 shares during the period. Natixis’ holdings in Bio-Rad Laboratories were worth $687,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BIO. Parallel Advisors LLC boosted its position in Bio-Rad Laboratories by 36.8% during the fourth quarter. Parallel Advisors LLC now owns 171 shares of the medical research company’s stock worth $55,000 after purchasing an additional 46 shares during the period. Signaturefd LLC boosted its holdings in shares of Bio-Rad Laboratories by 15.8% during the 4th quarter. Signaturefd LLC now owns 352 shares of the medical research company’s stock worth $114,000 after buying an additional 48 shares during the period. Gladius Capital Management LP grew its stake in Bio-Rad Laboratories by 65.8% in the 4th quarter. Gladius Capital Management LP now owns 121 shares of the medical research company’s stock valued at $39,000 after buying an additional 48 shares during the last quarter. Yousif Capital Management LLC raised its holdings in Bio-Rad Laboratories by 1.9% in the 4th quarter. Yousif Capital Management LLC now owns 2,775 shares of the medical research company’s stock worth $896,000 after acquiring an additional 51 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. lifted its position in Bio-Rad Laboratories by 7.7% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 836 shares of the medical research company’s stock worth $289,000 after acquiring an additional 60 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors.

Insider Activity at Bio-Rad Laboratories

In related news, EVP Michael Crowley sold 369 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $281.91, for a total value of $104,024.79. Following the sale, the executive vice president now directly owns 6,573 shares in the company, valued at approximately $1,852,994.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 17.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. UBS Group lowered their target price on Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Monday. Jefferies Financial Group reiterated a “hold” rating and set a $315.00 target price (down from $440.00) on shares of Bio-Rad Laboratories in a research note on Monday, June 3rd. Finally, Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $400.00 to $365.00 in a research report on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $436.67.

Bio-Rad Laboratories Trading Up 2.2 %

NYSE:BIO traded up $7.01 during mid-day trading on Friday, hitting $322.18. The company’s stock had a trading volume of 24,372 shares, compared to its average volume of 224,849. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.89 and a current ratio of 6.57. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $431.79. The stock has a fifty day moving average of $288.08 and a 200-day moving average of $307.15.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Tuesday, May 7th. The medical research company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.25. Bio-Rad Laboratories had a negative net margin of 12.37% and a positive return on equity of 3.59%. The company had revenue of $610.82 million during the quarter, compared to analysts’ expectations of $619.09 million. During the same quarter in the previous year, the company posted $3.34 earnings per share. Bio-Rad Laboratories’s quarterly revenue was down 9.8% compared to the same quarter last year. On average, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.8 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.